Tempus xE Whole Exome

xE is a whole exome 19,000+ gene panel by DNA seq that provides potentially actionable and biologically relevant alterations, TMB, as well as potential germline findings.

Ordering Flexibility

Tempus offers a variety of options to customize molecular profiling for patients.

  • xE and xR may be ordered as a standalone test or in combination
  • Streamlined ordering process through Tempus Hub, paper requisition, or directly from your EHR
Access Tempus Hub
image description


view all documents

    xE Requisition Form


    Specimen Guidelines

    Requires specimens with tumor content of at least 40% post macrodissection.


xE Performance Specifications

Variant Class Limit of Detection Sensitivity Specificity
Single Nucleotide Variants (SNVs) 10.0% VAF 99.4% 99.9%
Insertions and Deletions 10.0% VAF 97.1% 99.9%
Copy Number Gains 30.0% Tumor Purity 85.7% N/A

The analysis of xE paired normal match includes potential germline findings that may be reported in a limited set of 110 genes (including both hereditary cancer and non-cancer related genes) and may or may not be related to the patient’s current cancer diagnosis.* Potential germline gene selection for reporting was based on ACMG recommendations 1 , NCCN Guidelines Ⓡ2 , and other published literature.

Financial Assistance

We help provide access to our tests for all patients in financial need

Approval of the financial assistance application is based on your household income and takes into account all life circumstances. Once a financial assistance application is submitted either online or over the phone, you will receive a decision at the time of submission. 

  • Step 1

    Apply for financial assistance online at access.tempus.com.

  • Step 2

    If approved, you will know immediately about the maximum out-of-pocket cost of your testing.

  • Step 3

    Please contact billing@tempus.com if you are concerned about out-of-pocket costs and would like to discuss your options.

    All U.S.-based patients are eligible to apply for financial assistance regardless of insurance status. For uninsured and international patients, we offer a self-pay option. If you have any questions, please email patients@tempus.com.

* Normal match sequencing is utilized to ensure fidelity of somatic variant calling. Tempus xE is not a validated germline panel, and potential germline findings should not be used as a diagnostic determination for hereditary cancer risk.

  1. Miller DT, Rehm HL, Bale SJ, et al. ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021;23(8):1381-1390. doi:10.1038/s41436-021-01172-3.
  2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). ©National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed [6.2.23].

This is data-driven precision medicine

This is the future of healthcare.